Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep:193:190-197.
doi: 10.1016/j.thromres.2020.07.007. Epub 2020 Jul 7.

Preventing postpartum venous thromboembolism: A call to action to reduce undue maternal morbidity and mortality

Affiliations
Review

Preventing postpartum venous thromboembolism: A call to action to reduce undue maternal morbidity and mortality

Lauren Andrew et al. Thromb Res. 2020 Sep.

Abstract

Postpartum venous thromboembolism (VTE) is a leading cause of maternal mortality in developed countries and can carry significant long-term morbidity. Despite being able to identify postpartum VTE risk factors in a large proportion of the obstetrical population, there is little high-quality evidence available to guide practice on who should receive postpartum thromboprophylaxis. Based on epidemiological data, women with a prior history of VTE or known potent thrombophilia are likely to benefit from an extended duration of low-molecular-weight heparin (LMWH) prophylaxis. However, significant controversy exists around the benefit and harm of postpartum thromboprophylaxis in women with more modest risk factors, such as those with mild thrombophilias or transient situational risk factors around labor and delivery, such as cesarean delivery. We review the available data for postpartum VTE risk factors and thromboprophylaxis in these patients. This review highlights the latest evidence in the area of postpartum VTE prevention, and is a call to action for further research in this area to improve maternal morbidity and mortality.

Keywords: Postpartum; Thromboprophylaxis; Venous thrombosis.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest L.A.: No conflicts of interest to disclose; F.N.A: Unrestricted investigator-initiated research awards paid to institution (Leo Pharma, Actelion, Bayer); Advisory board membership (past 5 years): Bayer, BMS/Pfizer, Daiichi-Sankyo; M.B.: No conflicts of interest to disclose. M.A.R.: No conflicts of interest to disclose; L.S.: Research funding from CSL Behring; Honoraria from LEO Pharma.

Publication types

Substances

LinkOut - more resources